Sun Pharmaceutical Industries Limited has filed its unaudited financial results for the quarter ended June 30, 2026, with the National Stock Exchange of India Limited and BSE Limited. The disclosure marks the commencement of the company's reporting for FY27, providing stakeholders with an initial view of its performance in the new fiscal year. While the specific financial metrics are detailed in the full results available on the company’s website, the filing ensures regulatory compliance and timely dissemination of material information to investors.

The Board of Directors approved the results in a meeting held on July 31, 2026. Managing Director Kirti Ganorkar signed off on the communication, which was subsequently filed with the exchanges as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to disclose quarterly financial results within seven working days from the close of each quarter.

To further ensure transparency and reach a broader audience, Sun Pharma published newspaper advertisements on August 1, 2026. The advertisements appeared in all editions of Financial Express in English and the Ahmedabad Edition of Financial Express in Gujarati. These publications serve as a formal intimation under Regulation 30 of the SEBI LODR Regulations, ensuring that retail investors who may not track digital filings are also informed of the results.

Key Details of the Filing

Investors can access the complete unaudited financial statements, including standalone and consolidated figures, on the company’s website at www.sunpharma.com . The results are also available on the websites of the stock exchanges, www.bseindia.com and www.nseindia.com . A QR code provided in the advertisement allows users to scan and directly access the detailed financial report.

The filing process was overseen by Anoop Deshpande, the Company Secretary and Compliance Officer, who digitally signed the intimation on August 1, 2026. The company emphasized that the advertisement is for information purposes only and does not constitute an offer or invitation to purchase or sell securities. As with all quarterly filings, these results are subject to limited review by statutory auditors before final audit at the end of the fiscal year.

Sun Pharmaceutical Industries Limited has announced that all resolutions proposed at its 34th Annual General Meeting (AGM) were passed by shareholders with the requisite majority. The meeting, held on July 31, 2026, concluded successfully, with the independent Scrutinizer submitting his final report to the company confirming the outcome. This approval validates the corporate actions and strategic decisions outlined in the notice of the AGM dated July 06, 2026.

The resolutions are now effective in accordance with the applicable provisions of law. The company has submitted the official voting results to the relevant exchanges and stakeholders. The detailed Scrutinizer Report is accessible to investors and shareholders on the company’s website at www.sunpharma.com . This process ensures transparency and compliance with regulatory requirements governing general meetings.

Key Details of the 34th AGM

The following table summarizes the key procedural details of the recent annual general meeting:

Regulatory Compliance and Reporting

Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited, certified the results. The submission confirms that the voting process adhered to statutory guidelines. Shareholders are advised to refer to the company’s website for the complete Scrutinizer Report and voting breakdown. No further action is required from shareholders regarding these specific resolutions.